KRAS and neoplasm: Furthermore, we demonstrate that concurrent inhibition of multiple oncogenic RAS variants and wild-type RAS in the same tumour cell with a reversible broad-spectrum RASMULTI inhibitor such as RMC-7977 can overcome some of the resistance mechanisms recognized to limit the efficacy and durability for inactive-state KRAS(G12C) inhibitors.